Healthy Subjects
Conditions
Keywords
Healthy males and females
Brief summary
48 healthy adult male & female subjects will be enrolled in this study to determine the effect of Technosphere® Inhalation Powder (FDKP) on the QT interval of the EKG. Eligible subjects will be randomized into a dosing regimen after admission.
Detailed description
This is a Phase 1, randomized, double-blind, cross-over, placebo- and active-controlled cardiac safety study in 48 healthy subjects (both male and female subjects) designed to assess the effect of FDKP on cardiac repolarization, if any, following introduction of Technosphere® Inhalation Powder via inhalation. Each trial subject will be administered 20 mg of FDKP, 40 mg of FDKP, 400 mg oral dose of moxifloxacin (active), and placebo in a crossover design during an 11 day in-patient stay.
Interventions
DRUGTechnosphere Inhalation Powder (FDKP)
Technosphere® Inhalation Powder 20mg
DRUGMoxifloxacin
Tablets 400mg
DRUGPlacebo
Placebo cartridges
Sponsors
Mannkind Corporation
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Pulmonary Function Tests (PFTs) results within study specified limits. * Female subjects of childbearing potential must be non-pregnant and non-lactating and have a negative serum pregnancy test prior to enrollment into the trial. * Body Mass Index = 19 and = 30 kg/m2 * Absence of recent drug or alcohol abuse * Able to provide written informed consent, follow study procedures and remain in-patient for the entire treatment period * Non-smoking (\> 6 months)
Exclusion criteria
* History of significant renal, pulmonary, rheumatological, hematological, neurological or psychiatrics disorder * Clinically significant major organ disease * Evidence or history of clinically significant allergies (except for untreated, asymptomatic, seasonal allergies at time of dosing); * Current or previous chemotherapy or radiation therapy that could cause lung toxicity * History of diabetes or taking any medications to treat diabetes * Clinically significant abnormal findings on physical exam, ECG, vital signs, clinical laboratory testing and medical history * Hypokalemia (calcium below lower limit of normal). * Previous exposure to Technosphere® Inhalation Powder * Participation in another clinical trial of an investigational drug or device within 30 days prior to Visit 3 * Significantly excessive consumption of food or beverages with xanthine or caffeine * Unwilling to avoid alcohol 48 hours prior to study enrollment and during study * Unwilling to avoid strenuous activity for 48 hours prior to study enrollment and during study * Positive HIV or Hepatitis test * Any acute illness or fever within 72 hours of study dosing * Medication use (with exception of acetaminophen and hormonal birth control) or herbal use within 7 days of Visit 2 * Unwillingness to remain in a quiet, controlled environment (i.e., no TV, music, games, etc during specific timepoints) or unwilling to remain supine during specific timepoints * Unwillingness to consume a study-specific diet * Blood donation within 8 weeks prior to Visit 2 * History of chronic obstructive pulmonary disease (COPD), clinically proven asthma and/or any other clinically important pulmonary disease confirmed by pulmonary function testing and/or radiological finding * Active respiratory infection or persistent symptoms of such infection * History of risk factors for Torsades de pointes (TdP) \[e.g., heart failure, hypokalemia, family history (parents or siblings) of Long QT Syndrome\], history of fainting, unexplained loss of consciousness or convulsions * History of cardiac arrhythmia, of taking anti-arrhythmia drugs, significant cardiovascular dysfunction, myocardial dysfunction, cardiac surgery, transient attacks of ischemia or cerebrovascular accidents * An abnormal screening ECG which is interpreted by the Clinical Site Investigator to be clinically significant * Sustained supine resting systolic blood pressure \> 140 mm Hg or \< 100 mm Hg and /or diastolic blood pressure \>95 mm Hg at study entry Baseline pulse rate of \< 45 beats per minute or \> 100 beats per minute
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the time-matched, placebo-subtracted change from baseline in QTc after a supratherapeutic dose of Technosphere Inhalation Powder | 11 days |
Secondary
| Measure | Time frame |
|---|---|
| The maximum change in time-matched, placebo-subtracted QT interval corrected by Fridericia formula (QTcF) and Bazett formula (QTcB), respectively, for supratherapeutic dose of Technosphere® Inhalation Powder. | 11 Days |
| The maximum change in time-matched, placebo-subtracted QT/QTc intervals by Fridericia formula (QTcF), and by Bazett formula (QTcB), respectively, for therapeutic dose of Technosphere® Inhalation Powder. | 11 Days |
| Change in ECG morphological patterns | 11 Days |
| Heart rate and RR interval. | 11 Days |
| The time-matched change from baseline in QTc after therapeutic dose Technosphere® Inhalation Powder based on an individual correction (QTcI) method. | 11 days |
| QRS interval. | 11 Days |
| Correlation between the QTcI change from baseline and plasma concentrations of FDKP. | 11 Days |
| Plasma concentrations of FDKP. | 11 Days |
| PR interval. | 11 Days |
Countries
United States
Outcome results
None listed